STOCK TITAN

Aptose Biosciences, Inc. - APTO STOCK NEWS

Welcome to our dedicated page for Aptose Biosciences news (Ticker: APTO), a resource for investors and traders seeking the latest updates and insights on Aptose Biosciences stock.

Aptose Biosciences, Inc. (NASDAQ: APTO, TSX: APS) is a clinical-stage biotechnology company dedicated to developing precision medicines for the treatment of life-threatening cancers. This science-driven organization is focused on advancing first-in-class agents targeting acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and other hematologic malignancies. Based on a deep understanding of the genetic and epigenetic profiles of specific cancers and patient demographics, Aptose is building a robust pipeline of novel oncology therapies aimed at dysregulated processes and signaling pathways.

One of Aptose's pioneering agents, tuspetinib (TUS), is a highly potent, first-in-class pan-FLT3/BTK inhibitor. Developed as a small molecule therapeutic, tuspetinib targets various key kinases such as SYK, FLT3, JAK1/2, and mutant forms of KIT, RSK2, and TAK1-TAB1. This mechanism of action not only combats the proliferation of AML cells but also minimizes the typical cytotoxic side effects associated with conventional cancer treatments, thus enhancing the quality of life for patients.

Tuspetinib has shown significant promise in ongoing clinical trials. In the APTIVATE Phase 1/2 study, tuspetinib, both as a monotherapy and in combination with venetoclax (VEN), has demonstrated favorable safety profiles and robust efficacy in relapsed/refractory AML patients. This includes patients with various genetic mutations and those who have failed prior therapies. Notably, tuspetinib has demonstrated a 48% overall response rate when used in combination with venetoclax, making it a potential candidate for accelerated approval in difficult-to-treat VEN-resistant AML cases.

Aptose is also developing luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor currently in Phase 1 a/b development. Luxeptinib targets relapsed or refractory hematologic malignancies and is being positioned for future clinical trials using its new generation 3 (G3) formulation, which has shown improved pharmacokinetics and tolerability.

Recently, Aptose has entered strategic financial transactions, including a public offering and private placement, to support the further development of tuspetinib and general corporate activities. With strong clinical data and robust financial backing, Aptose continues to make strides in the oncology field, aiming to bring life-saving treatments to patients in need.

Rhea-AI Summary

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced it will release financial results for the year and quarter ended December 31, 2021, on March 22, 2022, post-market close. The report will include a corporate update. A conference call is scheduled for the same day at 5:00 PM ET, accessible via dial-in and webcast. Key products in Aptose's pipeline include two oral kinase inhibitors aimed at treating hematologic malignancies, currently undergoing various clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
conferences earnings
-
Rhea-AI Summary

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference on March 15, 2022. William G. Rice, Ph.D., Chairman, President, and CEO, will present and host one-on-one meetings during the event. The virtual presentation is scheduled from 10:00 to 10:30 ET. Interested parties can access the webcast through Aptose's website or directly via a provided link. Aptose specializes in developing personalized oncology therapies, currently focusing on treatments for hematologic malignancies, including two investigational products in clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) will participate in two key biotech events in January 2022: the H.C. Wainwright BIOCONNECT Virtual Conference (January 10-13) and the 11th Annual LifeSci Partners Corporate Access Event (January 5-7). The management team will host investor meetings at both events. Aptose focuses on developing innovative cancer therapies, with products like HM43239 and luxeptinib aimed at treating hematologic malignancies. For more details, visit www.aptose.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
conferences
Rhea-AI Summary

Aptose Biosciences Inc. (NASDAQ: APTO) announced the discontinuation of clinical development for APTO-253, following an internal review and a clinical hold from the FDA. The focus will shift to advancing their kinome inhibitor pipeline, specifically HM43239 and luxeptinib, which have shown promising clinical activity in hematologic malignancies. The company is exploring strategic alternatives for APTO-253. This decision underlines Aptose's commitment to addressing unmet medical needs in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
none
-
Rhea-AI Summary

Aptose Biosciences has reported promising results for its oral myeloid kinome inhibitor HM43239, presented at the 2021 ASH Annual Meeting. The drug showed durable activity in patients with relapsed or refractory acute myeloid leukemia (AML). Key highlights include a 37.5% complete response rate among FLT3 mutant patients at the 80 mg dose. The Phase 1/2 trial enrolled 34 patients, showing a favorable safety profile. Additionally, data for luxeptinib and APTO-253 were shared, showcasing their potential in treating hematologic malignancies. Aptose aims to expand its clinical portfolio significantly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-43.08%
Tags
none
-
Rhea-AI Summary

Aptose Biosciences Inc. (NASDAQ: APTO) provided an update on its clinical developments on November 29, 2021, ahead of its corporate presentation on December 13, 2021. The presentation will highlight data from the oral Phase 1/2 trial of HM43239, an oral myeloid kinome inhibitor targeting relapsed or refractory acute myeloid leukemia (AML). Additionally, the status of luxeptinib, a dual lymphoid and myeloid kinome inhibitor, will be discussed. Both compounds are part of Aptose's continued commitment to advancing therapies for unmet needs in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.39%
Tags
none
Rhea-AI Summary

Aptose Biosciences (Nasdaq: APTO; TSX: APS) announced its participation in the virtual Piper Sandler 33rd Annual Healthcare Conference, scheduled from November 23 to December 2, 2021. The company will present a pre-recorded fireside chat, which will be accessible on the conference website and through Aptose's official site. Additionally, management will engage in 1-on-1 investor meetings during the event. Aptose focuses on personalized oncology therapies, with a pipeline that includes three clinical-stage products targeting hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
conferences
-
Rhea-AI Summary

Aptose Biosciences reported a net loss of $11.3 million for Q3 2021, a decrease from $13.2 million in Q3 2020. Total cash as of September 30, 2021, was $95.1 million, projected to fund operations into early 2023. The company advanced its pipeline with HM43239, a myeloid kinome inhibitor, and increased the dose of Luxeptinib in ongoing clinical trials. Significant reductions in general and administrative expenses were observed. Aptose plans a conference call at 5 PM ET today to discuss these results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
Rhea-AI Summary

Aptose Biosciences (NASDAQ: APTO) announced the acceptance of clinical data for its myeloid kinome inhibitor HM43239 for oral presentation at the 63rd ASH Annual Meeting in December 2021.

Additionally, data for Luxeptinib and APTO-253 have been accepted for poster presentations. The oral presentation is scheduled for December 13, 2021, while poster presentations will occur on December 11 and 13.

The presentations will feature new data and an investor event will provide further details.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Aptose Biosciences (Nasdaq: APTO) has secured an exclusive license for HM43239 from Hanmi Pharmaceutical, aimed at treating acute myeloid leukemia (AML). This highly potent oral myeloid kinome inhibitor has shown promising results, achieving multiple complete responses in ongoing clinical trials. The agreement includes a $12.5 million upfront payment, comprised of cash and shares, with potential milestone payments totaling $407.5 million. The CEO of Aptose expressed strong confidence in HM43239's commercial viability and strategic alignment with their focus on hematologic malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Aptose Biosciences (APTO)?

The current stock price of Aptose Biosciences (APTO) is $0.25 as of December 24, 2024.

What is the market cap of Aptose Biosciences (APTO)?

The market cap of Aptose Biosciences (APTO) is approximately 14.9M.

What does Aptose Biosciences specialize in?

Aptose Biosciences focuses on developing precision medicines for treating life-threatening cancers, particularly acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

What is tuspetinib?

Tuspetinib (TUS) is a first-in-class pan-FLT3/BTK inhibitor being developed by Aptose for the treatment of AML. It targets key kinases to combat cancer cell proliferation while minimizing side effects.

What are the recent achievements of Aptose Biosciences?

Aptose has shown significant clinical efficacy for tuspetinib in treating relapsed/refractory AML, including a 48% overall response rate in combination with venetoclax. The company has also secured strategic financial investments to support its clinical programs.

What is luxeptinib?

Luxeptinib (CG-806) is an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b development. It is designed to treat relapsed or refractory hematologic malignancies and has demonstrated improved pharmacokinetics with its new G3 formulation.

How does Aptose aim to improve the quality of life for cancer patients?

Aptose focuses on developing targeted therapies based on a patient’s specific genetic profile to enhance treatment efficacy and reduce cytotoxic side effects, thereby improving the quality of life for cancer patients.

What financial activities has Aptose recently undertaken?

Aptose recently closed public offerings and private placements to raise funds for the clinical development of tuspetinib and for general corporate purposes.

What are the main clinical trials conducted by Aptose?

The main clinical trials include the APTIVATE Phase 1/2 study of tuspetinib in relapsed/refractory AML patients and Phase 1 a/b studies for luxeptinib targeting hematologic malignancies.

What makes tuspetinib a potential candidate for accelerated approval?

Tuspetinib has shown significant clinical efficacy and a favorable safety profile, particularly in combination with venetoclax for treating difficult-to-treat VEN-resistant AML patients, which may expedite its approval process.

How does Aptose integrate genetic insights into its drug development?

Aptose leverages genetic and epigenetic insights into specific cancers and patient populations to build a pipeline of novel therapies targeting dysregulated processes and signaling pathways.

What is the strategy behind Aptose's targeted therapies?

Aptose's strategy involves developing targeted medicines for precision treatment based on a patient’s specific gene expression signature, aiming to enhance efficacy while minimizing side effects.

Aptose Biosciences, Inc.

Nasdaq:APTO

APTO Rankings

APTO Stock Data

14.88M
56.33M
16.38%
16.68%
0.62%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
TORONTO